



**Biennial Montie Shumaker Kidney Cancer Lecture
Tuesday, October 8, 2024**

**“Moving towards biomarker-based Treatment in Renal Cell
Carcinoma”**

Visiting Professor

Brian I. Rini, MD, FASCO

Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center (VICC)
Ingram Professor of Medicine at Vanderbilt University

***Breakfast will be provided at 7:30am F2305 MCHC Auditorium**

Lecture at 8:00am-9:00am in the F2305 MCHC Auditorium




Brian I. Rini, MD, FASCO, is the Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Professor of Medicine at Vanderbilt University, where he leads kidney cancer clinical research efforts and the expansion of cancer clinical research operations. His research activities include over 300 publications extensively covering genitourinary cancer, most notably renal cell carcinoma. Dr. Rini has been lead investigator of several phase 3 clinical trials which have led to FDA approval. He has spoken at numerous seminars and invited lectureships, locally, nationally, and internationally, on genitourinary cancers and their treatments. He recently completed a term as a member and past Chair of the Oncologic Drugs Advisory Committee (ODAC). Dr. Rini is also co-host of the popular GU Oncology-focused podcast ‘Uromigos’.

Dr. Montie received his MD in 1971 from the University of Michigan. He completed his urologic surgery residency at the Cleveland Clinic Foundation in 1976, and after two years in the Air Force, proceeded to Memorial Sloan-Kettering Cancer Center in 1978 to study urologic oncology. After stints at the Cleveland Clinic and Wayne State University, in 1995 he joined the University of Michigan with the rank of Professor of Surgery and was awarded the Valassis Professor of Urologic Oncology the following year. He was promoted to Head of the Section of Urology in 1997 and was Founding Chairman of the Department of Urology in 2001—a position he held until 2007.



In 2005, he established the Division of Health Services Research (HSR) at the University of Michigan. This has grown to be the largest and arguably most prominent urologic HSR group in the world. In 2016, he was awarded the Lifetime Achievement Award from the AUA and the Distinguished Mentor Award, Michigan Institute for Clinical and Health Research, University of Michigan.

The Montie Shumaker Lecture Series in Renal Cell Cancer seeks to bring leading voices in the research and treatment of Renal Cell Cancer to southeastern Michigan. It is named in honor of Dr. James Montie, the founding chairman of the University of Michigan Department of Urology and his friend and former patient, Tom Shumaker. Aided by cutting-edge treatment from specialists like Dr. Montie, Mr. Shumaker lived and thrived as a renal cell cancer patient for over 20 years. During this time, he defied conventional thought of what life with cancer looks like and was a source of inspiration and hope for all of those around him. This lecture series is made possible by a gift from his wife, Sharon Shumaker.



For more information, contact Evelyn DiCola at dicolaev@med.umich.edu (734) 615-6662